Engflag

Nofluzone

Quick links to important sections

Nofluzone

Nofluzone_EN

Method of action: Antifungal Broad Spectrum

Treatment option: Balanitis, Vaginal Candidiasis, Histoplasmosis, Fungal Infection, Fungal Infection,Fingernail, Jock Itch, Immunodeficiency, Infection, Candidemia, Candidiasis,Vaginal

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nofluzone

Quick Facts

Property Description
Active ingredient Fluconazole
Form Capsule, Tablet, Suspension, Injection
Pharmacological class Triazole Antifungal Agent
Common use Systemic Fungal Infections
Origin Synthetic

Nofluzone is a prescription medicine used for treating infections caused by fungi and yeasts throughout the body. Its therapeutic identity is defined by its sole active ingredient, Fluconazole, a highly effective, synthetic compound within the azole class of antimicrobials. The drug's general purpose is to provide systemic control over fungal pathogens that can cause widespread or persistent infections, such as those that may affect immunocompromised hosts.

What Type of Medicine is Nofluzone? (Identity and Class)

Nofluzone is classified as a triazole antifungal agent, representing a subclass of antifungal medicines specifically developed for systemic use. Fluconazole, the active ingredient (International Nonproprietary Name, INN), is a synthetic derivative recognized as a first-generation triazole. This classification signifies its focused action against fungal organisms, separating it from agents used for bacterial or viral infections. Fluconazole exhibits high oral bioavailability, meaning the majority of the drug is absorbed into the bloodstream when taken by mouth. This indicates the medicine is well-absorbed when taken orally.

Composition and Forms: A Systemic Approach

The core composition of Nofluzone is the single active substance, Fluconazole, formulated with various solid and aqueous bases to ensure efficient systemic delivery. This medicine is a single-component product available in multiple pharmaceutical preparations to suit different patient needs and administration preferences. These include oral options such as the capsule, tablet, and oral suspension, intended for oral administration, alongside a sterile solution for injection suitable for intravenous infusion when immediate or non-oral delivery is required. The availability of both oral and intravenous forms is a key distinguishing factor, offering flexibility in treating severe or deep-seated infections.

The Function: Why Fluconazole is an Antifungal Agent

The function of Nofluzone is to act as a fungistatic agent, which means its primary role is to limit the growth and reproduction of the fungal cells responsible for the infection. Its fundamental action involves the disruption of the fungal cell's structure by interfering with the synthesis of ergosterol, a critical structural component of the fungal cell membrane. Fluconazole inhibits the fungal cytochrome P450 enzyme 14alpha-demethylase (also known as lanosterol demethylase). This confirms the medicine works by disrupting the crucial building blocks of the fungal cell. By preventing the fungal cells from multiplying, this mechanism contains the infection and facilitates its clearance by the body's immune system.

What side effects are possible with Nofluzone?

Possible side effects and safety information

Nofluzone (Fluconazole) safety is officially classified by government regulatory documents based on the type and frequency of documented adverse reactions, generally grouped by the affected System-Organ-Class (SOC).

Adverse Reaction Classification

Adverse effects are categorized based on their frequency observed in clinical trials and post-marketing data:

Classification Examples of Documented Effects
Common (1/100 to 1/10) Headache, abdominal pain, nausea, vomiting, diarrhea, and elevated liver enzymes (transaminases).
Uncommon (1/1,000 to 1/100) Dizziness, somnolence, vertigo, change in taste, muscle pain, and fever.
Rare (1/10,000 to 1/1,000) Anaphylaxis, seizures, hepatic necrosis, QT interval prolongation, and Stevens-Johnson Syndrome.

Serious Adverse Reactions and Restrictions

Official labeling highlights the potential for serious hepatic toxicity, including rare reports of fatalities, which necessitates close monitoring of liver function. Life-threatening ventricular arrhythmias, specifically QT interval prolongation and Torsade de Pointes, are documented as rare but serious cardiac events, particularly in patients with pre-existing heart conditions or electrolyte abnormalities. For skin and subcutaneous tissues, severe exfoliative reactions, such as Toxic Epidermal Necrolysis (TEN), are also listed as rare but serious risks.

Use of Nofluzone is strictly contraindicated in individuals with known hypersensitivity to the medicine or other azole derivatives. Co-administration with certain medications known to prolong the QT interval is also prohibited due to the increased risk of cardiotoxicity, as defined in regulatory texts.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Suspected overdose of Nofluzone requires immediate medical attention. The official regulatory profile for this medicine documents specific clinical manifestations following excessive intake, primarily affecting the central nervous system (CNS) and the cardiovascular system.

Documented presentations include severe neuropsychiatric events such as hallucinations and paranoid behavior. Furthermore, acute overexposure is associated with the risk of seizures. The most serious potential outcome listed in regulatory documents is the risk of QT interval prolongation, a documented cardiac risk that may progress to the life-threatening abnormality Torsade de Pointes.

Management and Required Action

Management of Nofluzone overdose is based on regulatory guidance and must be symptomatic and supportive. It is officially stated that no specific antidote is known to reverse the effects of the compound. Due to the risk of cardiotoxicity, continuous ECG monitoring is warranted in a medical facility.

Procedural measures documented for reducing systemic exposure include gastric lavage if clinically appropriate, and hemodialysis. Hemodialysis is officially noted as being capable of substantially reducing the drug's plasma concentration. Individuals must seek immediate medical attention for any suspicion of overdose or if the documented CNS or cardiac symptoms are observed.

Therapeutic Uses of Nofluzone

What Nofluzone Treats: Main Uses and Benefits

Nofluzone is applied across domains where additional symptomatic support is needed. In situations where patients experience symptoms associated with acute or episodic changes, it is relevant for managing symptoms that interfere with daily comfort. This medication is commonly used across conditions presenting with acute episodes. It is used for managing symptoms related to physical discomfort, heightened physiological activity, and systemic imbalance.

The medicine is relevant in contexts marked by increased discomfort or tension, applied when symptoms become temporarily overwhelming. It contributes to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes. It also helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact Block

Application: Addressing Physical Discomfort

Nofluzone helps address symptom clusters that may become intense or disruptive, supporting general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview on Acetaminophen

Eligibility and Restrictions for Use

The medicine Nofluzone is regulated for use across a wide age spectrum but includes strict population limitations defined by health authorities.

Eligibility scope

Category Regulatory Status
Populations for whom use is contraindicated Absolute prohibition for patients with hypersensitivity to the drug or other azole antifungals; also forbidden when co-administered with certain drugs, such as cisapride or pimozide.
Populations for whom use is restricted Renal Impairment requires a regulatory dose adjustment; Hepatic Impairment requires caution and close monitoring.
Age-related eligibility rules Use is established in adults and pediatric patients, including neonates, with specific rules for infants. Older adults require renal function review.
Pregnancy and lactation eligibility Not Recommended during pregnancy unless treating severe or life-threatening infections; high-dose chronic use is highly restricted. Breastfeeding is not recommended during repeated therapy.

Resulting eligibility structure

The official regulatory documents define who can and cannot use Nofluzone by establishing boundaries based on patient risk factors, physiological state, and existing medical conditions. Eligibility is determined through a hierarchy that includes absolute contraindications, restricted use based on organ function, and specific caution tied to comorbidities, such as risk factors for QTc prolongation or uncorrected electrolyte imbalances.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Nofluzone

Interaction Scope

Category Documented Regulatory Information
Medicinal product categories with documented interactions Oral Anticoagulants, Sulfonylureas, Statins, Immunosuppressants, Agents that prolong the QT interval.
Specific interacting medicines (if explicitly listed) Astemizole, Cisapride, Pimozide, Warfarin, Phenytoin, Rifampin, Cyclosporine, Atorvastatin, Simvastatin, Cimetidine.
Mechanistic basis of interactions (only if stated in label) Potent inhibition of CYP2C9; Moderate inhibition of CYP3A4; Inhibition of CYP2C19. Pharmacodynamic effect increasing Prothrombin Time (INR).
Timing-based interaction rules (if applicable) No mandatory, dose-spacing rules are explicitly detailed in the regulatory labeling.
Population-specific interaction notes (if applicable) Renal Dysfunction markedly affects pharmacokinetics; Elderly patients show generally higher systemic exposure (AUC).
Interaction-related restrictions Formally contraindicated for co-administration with Astemizole, Cisapride, Pimozide, and high-dose Terfenadine.

Interaction Classifications (High-Level)

Category Official Regulatory Classification/Basis
Interaction severity classification Contraindicated (e.g., with Pimozide); Clinically Significant (e.g., with Warfarin, Statins); Exposure-Reducing (e.g., with Rifampin).
Regulatory basis Prescribing Information (FDA), Summary of Product Characteristics (EMA).
Interaction-context constraints Use is restricted with sensitive CYP3A4 substrates that prolong the QT interval. The co-administration of food does not alter systemic exposure.

Resulting Interaction Structure

Nofluzone’s official interaction profile is structured around its documented activity as a potent inhibitor of the enzyme CYP2C9 and a moderate inhibitor of CYP3A4. This pharmacokinetic effect results in documented increases in the plasma concentrations and systemic exposure of co-administered medicines that are metabolized by these enzymes. For example, co-administration with Warfarin is officially stated to increase Prothrombin Time and INR, and Statins experience increased systemic levels due to reduced clearance. In terms of severity, co-administration with specific agents that prolong the QT interval, such as Astemizole, Cisapride, and Pimozide, is formally contraindicated in regulatory labeling due to the associated cardiac risk. Conversely, substances known as enzyme inducers, such as Rifampin, are documented to cause a clinically significant decrease in Nofluzone’s own systemic exposure. Furthermore, the official labeling notes that Nofluzone’s pharmacokinetics are markedly affected by reduced renal function, and systemic exposure (AUC) is generally higher in the elderly population.

Mechanism of Action

Inhibition of Fungal Ergosterol Biosynthesis

Nofluzone's mechanism centers on the highly selective inhibition of the fungal enzyme lanosterol 14alpha-demethylase (CYP51). By blocking this crucial enzyme, the molecule immediately halts the synthesis of ergosterol, the essential sterol required to maintain the structural integrity and fluidity of the fungal cell membrane. This action results in fungistatic activity through the disruption of the pathogen's core metabolic pathway.

Structural Failure and Pathogen Compromise

The resulting depletion of ergosterol, combined with the pathological accumulation of toxic intermediate sterols, significantly compromises the fungal cell membrane. This structural failure leads to excessive permeability and the uncontrolled leakage of cellular contents, thereby preventing the fungus from successfully growing, replicating, or sustaining itself. This mechanism underlies the drug's pharmacological activity, although its inhibitory effect can be constrained by fungal efflux pumps that actively reduce the intracellular drug concentration.

Dosage and Administration Information

How Nofluzone is Used

Nofluzone (Fluconazole) administration follows standardized protocols across its approved forms, defining its route, dose, and frequency for clinical use. The daily dosage is equivalent for both the oral and intravenous routes, reflecting the drug's high oral bioavailability.

Official Administration Protocols

Protocol Description
Route of Administration Approved for both oral intake (capsule, tablet, suspension) and intravenous (IV) infusion (injection solution).
Dosing Schedule Therapy begins with a loading dose (typically double the maintenance amount) on Day 1, followed by a lower maintenance dose thereafter. Maintenance ranges from 50 mg to 400 mg once daily.
Frequency and Duration The standard frequency is once daily. The overall course duration varies, ranging from a single dose for certain conditions to potentially indefinite suppressive therapy for high-risk patients.

Practical Administration Guidance

For oral consumption, the medicine may be taken with or without food as the gastrointestinal absorption is not significantly affected. If administering the oral suspension, it must be shaken well and measured using a calibrated device.

When using the intravenous solution, the infusion is typically administered at a controlled speed, with a maximum rate not exceeding 200 mg per hour.

Dose Adjustments for Renal Function

Specific dose reductions are required for patients with impaired kidney function. For adults with a Creatinine Clearance le 50 mL/min, the maintenance dose must be reduced to 50% of the standard recommendation. For patients undergoing hemodialysis, a full standard dose is administered after each dialysis session to account for drug clearance.

Recent Clinical Evidence

Nofluzone: Recent Clinical Evidence

The clinical evidence for Nofluzone is drawn from established research, including Randomized Controlled Trials (RCTs), comparative studies, and large-scale meta-analyses. This research provides context for the medicine's use by describing which populations were studied and what outcomes were monitored, without providing clinical advice.

Evidence for Systemic Fungal Infections

Research has extensively examined the medicine in the context of systemic fungal infections, particularly those caused by Candida species in the bloodstream. RCTs and high-quality observational studies were primarily utilized, focusing on populations of hospitalized adults and those in critical care settings. Studies monitored key outcomes such as clinical response, mycological status (change in fungal culture results), and overall patient mortality. Findings describe patterns related to mycological status and measured differences in fungal-related mortality compared to overall mortality.

Evidence for Mucosal Fungal Infections

The evidence base for mucosal infections, such as oral and esophageal candidiasis, relies heavily on Randomized Controlled Trials. Researchers examined outcomes related to clinical response and the subsequent rate of disease relapse or recurrence. Reports described patterns related to measured rates for clinical response and mycological status when outcomes were measured across short-term treatment periods. Evidence for long-term recurrence patterns remains limited in general populations, with most of the extended follow-up data derived from highly immunocompromised cohorts.

Research on Long-Term Outcomes and Uncertainty

The durability of the medicine's effect has been examined primarily through systematic reviews and meta-analyses that aggregate data from multiple prophylactic RCTs. These studies monitored the incidence of Invasive Fungal Infections (IFI) and overall mortality. Research has documented findings indicating measured differences in the incidence of IFI between study groups. However, measured outcomes for overall patient mortality across different trials demonstrated mixed findings, and the data on the impact on overall survival has shown variability. Follow-up durations were limited in certain trials, meaning there is limited information for long-term outcomes.

Frequently Asked Questions (FAQ)

Common questions about Nofluzone (FAQ)

Q: Can Nofluzone cure a common yeast infection after just one dose?

Studies and official information indicate that a single-dose regimen is established for the treatment of certain common yeast infections, such as vaginal candidiasis. Clinical trials related to this specific use have reported a favorable clinical response rate in studied populations. This demonstrates that for some conditions, a single treatment is a recognized option.

Q: What should I do if my oral suspension bottle freezes?

Official storage instructions state that the liquid oral suspension must be protected from freezing to maintain its quality. If the product does freeze, regulatory documents require it to be discarded as it may no longer be effective or safe. Patients whose medicine has been compromised are often advised to contact their healthcare professional or pharmacist for guidance.

Q: What is the safe time period to use Nofluzone after the oral suspension is mixed?

According to the official product information, once the dry powder is mixed with water (a process called reconstitution), the oral suspension has a defined stability period. Official product information generally states that any unused portion must be discarded after 14 days from the time it was mixed. This beyond-use date must be observed to ensure the medicine remains stable and effective.

Q: Can I drink alcohol while I am taking Nofluzone?

Regulatory documents do not list alcohol as a formal drug-drug interaction that prohibits use. However, Nofluzone does carry a warning about the potential for serious liver injury (hepatic toxicity). Because of this, regulatory information advises patients to consult their doctor regarding alcohol consumption while taking this medication.

Q: Is Nofluzone a generic drug, or is it a brand name?

Nofluzone is a name used to refer to the drug with the active ingredient Fluconazole, which is the generic name. Regulatory records show that Fluconazole is available as both a brand-name product (such as Diflucan) and in various generic formulations. This means that different manufacturers produce the same active medicine.

How should Nofluzone be stored and disposed of?

The official regulatory documents specify strict conditions for storing and disposing of Nofluzone (Fluconazole) to ensure product quality and public safety.

Storage Requirements

Formulation Required Temperature Stability Constraint
Capsules/Tablets Controlled Room Temperature (15 C to 30 C) Store in original container.
Oral Suspension (Reconstituted) 5 C to 30 C Discard any unused portion after 14 days.

All liquid forms (suspension and injection) must be protected from freezing. If the oral suspension freezes, it must be discarded. The medication must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Nofluzone should be disposed of by following official guidelines. Prioritize drug take-back programs when available. If a take-back option is not accessible, unused medicine should be mixed with an unappealing substance, sealed in a plastic bag, and placed in the household trash. The medication must not be disposed of by flushing it down a toilet or pouring it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagEcuador

Equivalent of Nofluzone found in:

A-Z Index: